Orthobond Welcomes George Landau as EVP of Business Development
Orthobond Corporation recently made significant headlines by appointing George Landau as the Executive Vice President of Business Development and Commercialization. This strategic addition comes as the company continues to enhance its position in the medical device industry, specifically in developing innovative antibacterial surface technologies. As the driving force behind the company's future growth, Landau will focus on strategic partnerships and the commercialization of Orthobond's proprietary antibacterial solution, OSTAGUARD.
Expertise in Medical Device Industry
With over three decades of experience in the life-science sector, George Landau brings a wealth of knowledge and a successful track record to Orthobond. His career has included pivotal roles in business and corporate development across various fields, including medical devices, pharmaceuticals, and digital health. Furthermore, he has been instrumental in leading high-profile mergers and acquisitions, showcasing his ability to drive company growth and value creation.
Leadership Experience
Before his tenure at Orthobond, Landau was the President of Alpha MedTech Advisors, where he provided strategic advice and support for notable industry clients. His previous executive roles at ConvaTec Group, CR Bard, and Johnson & Johnson’s Cordis Corporation have equipped him with comprehensive insights into market trends and competitive analysis, making him a valuable asset to Orthobond's leadership team. His strategic acumen in identifying and implementing new business opportunities is critical as the company seeks to expand its market reach.
Commitment to Innovation and Quality
Orthobond's CEO, David Nichols, expressed enthusiasm about Landau's appointment, emphasizing the importance of his experience in navigating the complexities of the medical device industry. Nichols stated, “With George’s indispensable expertise and proven track record of success within the medical device industry, we are poised to tackle the next stage of our company’s growth.” This commitment to innovation aligns with Orthobond's mission to develop breakthrough solutions that address bacterial contamination in medical device implants.
Impact on Orthobond's Future
As Orthobond steps into a transformative phase, Mr. Landau's role will be pivotal in advancing the company's efforts to reduce bacterial contamination on medical device implants. His vision for expanding commercialization efforts will play a crucial role in further establishing Orthobond's leadership in the orthopedic and clinical markets. “I am thrilled to be joining Orthobond during this exciting moment in its growth trajectory and to help expand and accelerate its commercialization efforts,” said Mr. Landau.
Expansion and Future Goals
The addition of Mr. Landau is part of Orthobond's broader strategy aimed at bolstering its workforce and enhancing its offerings following De Novo marketing clearance from the FDA. The company’s innovative OSTAGUARD surface solution represents a significant step forward in the fight against bacterial contamination, leveraging unique surface modifications that bind actively to surfaces while eliminating pathogens without traditional antibiotics.
About Orthobond Corporation
Orthobond Corporation stands at the forefront of antibacterial surface technology, offering solutions that extend across various industries, including medical devices, automotive, and more. Their proprietary technology is designed to create surfaces capable of combating bacteria effectively without relying on eluting antibiotics. Their advancements in surface modification technology ensure a safer and more effective way to address the challenges posed by bacteria in critical applications.
Frequently Asked Questions
What is George Landau's role at Orthobond?
George Landau serves as the Executive Vice President of Business Development and Commercialization, focusing on strategic partnerships and driving commercialization efforts.
What is OSTAGUARD?
OSTAGUARD is Orthobond's proprietary antibacterial, non-eluting surface solution aimed at reducing bacterial contamination in medical device implants.
What is Orthobond's mission?
Orthobond's mission is to develop innovative technologies that prevent bacterial contamination in medical devices through advanced surface modifications.
How does Landau's experience benefit Orthobond?
Landau’s extensive experience in the life-science sector positions him to effectively lead strategic growth initiatives and partnerships, enhancing company performance.
Where can I learn more about Orthobond?
For more information on Orthobond Corporation and its innovative solutions, please visit their official website.
